[Remission under treatment of cutaneous xanthomatosis disclosing myeloma: apropos of a case with a three-year course].
We report a case of IgG lambda multiple myeloma with inaugural cutaneous xanthomatosis. A three years follow up showed parallel evolution of xanthomatosis and monoclonal gammapathy during therapy suggesting that the association is not coincidental. A decrease in IDL catabolism could be responsible. The monoclonal gammapathy could react with IDL and disturb the recognition of apolipoprotein E by its hepatic receptor.
Gancel
A
A
Service de Médecine Interne, Hôpital de Boisguillaume, Boisguillaume.
Lévesque
H
H
Mabilais
P
P
Daragon
A
A
Courtois
H
H
D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D010265:Paraproteinemias / Q000150:complications; D011241:Prednisone / Q000627:therapeutic use; D012871:Skin Diseases / Q000175:diagnosis / Q000209:etiology; D013997:Time Factors; D014973:Xanthomatosis / Q000175:diagnosis / Q000209:etiology*
D003520:Cyclophosphamide; D011241:Prednisone
Régression sous traitement d'une xanthomatose cutanée révélatrice d'un myélome: à propos d'un cas avec 3 ans d'évolution.